Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Official title: To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
More subjectsShow fewer subjects
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Message on Senate action sent to the House.
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
- grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
- grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
- a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
- Engrossed in House Formatted Text PDF Formatted XML
- Enrolled Bill Formatted Text PDF Formatted XML United States Legislative Markup
- Introduced in House Formatted Text PDF Formatted XML
- Placed on Calendar Senate Formatted Text PDF Formatted XML
- Reported in House Formatted Text PDF Formatted XML
- TWENTY-FIRST CENTURY GROUP, INC.
- THE ALS ASSOCIATION
- I AM ALS
- THE ALS ASSOCIATION
- TWENTY-FIRST CENTURY GROUP, INC.
- MUSCULAR DYSTROPHY ASSOCIATION, INC.
Bodies those filers lobbied
- HOUSE OF REPRESENTATIVES
- SENATE
- Defense, Dept of (DOD)
- Food & Drug Administration (FDA)
- Health & Human Services, Dept of (HHS)
- Agriculture, Dept of (USDA)
- Centers For Disease Control & Prevention (CDC)
- Centers For Medicare and Medicaid Services (CMS)
Cite this page
U.S. Congress. (2026). H.R. 8205: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026. 119th Congress. Open America. https://openamerica.io/bill/119-HR-8205/
"H.R. 8205: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-8205/.
H.R. 8205, 119th Cong. (2026), https://openamerica.io/bill/119-HR-8205/.
[H.R. 8205: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026](https://openamerica.io/bill/119-HR-8205/)